PCSK9
HGNC:20001 · 66 retained evidence mentions
Source-grounded findings
Supporting evidence
| Type | Entity | Source evidence | Confidence | Extractor |
|---|---|---|---|---|
| gene | PCSK9 | “BACKGROUND AND AIMS: Familial hypercholesterolemia (FH), primarily caused by pathogenic LDLR, APOB, or PCSK9 variants, results in elevated LDL-C and increased cardiovascular risk.” | 0.98 | hgnc_dict_v1 |
| gene | PCSK9 | “Selenium-Astaxanthin Co-Supplementation Synergistically Reduces PCSK9 Expression, Upregulates LDL Receptors, and Improves lipid profile and Cardiovascular Markers in Menopausal Ovariectomized Rats by attenuating inflammation and lipid peroxidation.” | 0.98 | hgnc_dict_v1 |
| gene | PCSK9 | “Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9)-targeted therapies, which include monoclonal antibodies (evolocumab, alirocumab) and small interfering RNA (inclisiran), offer potent LDL-C lowering that can help address this gap.” | 0.98 | hgnc_dict_v1 |
| gene | PCSK9 | “Epiafzelechin, a Flavanol, Regulates Lipid Homeostasis Through Modulation of HMGCR, PCSK9, and PPAR-α: Mechanistic Insights and Therapeutic Implications.” | 0.98 | hgnc_dict_v1 |
| gene | PCSK9 | “PCSK9 as a Biomarker and Therapeutic Target for Anthracycline Cardiotoxicity Prevention: Recent Advancements and Future Perspectives.” | 0.98 | hgnc_dict_v1 |
| gene | PCSK9 | “Meta-Analysis of Oral PCSK9 Inhibitors for Hypercholesterolemia in Adults: A Systematic Review and GRADE Assessment.” | 0.98 | hgnc_dict_v1 |
| gene | PCSK9 | “The possible role of PCSK9 inhibitors in cardiac syndrome X: Bridging microvascular dysfunction, endothelial pathobiology, and molecular pharmacotherapy.” | 0.98 | hgnc_dict_v1 |
| gene | PCSK9 | “Cholesterol acts as a metabolic cue that reshapes diverse signaling networks, including hedgehog and several sterol-regulated pathways orchestrated by key proteins, including sterol regulatory element-binding protein 2 (SREBP2), sterol O-acyltransferase 1 (SOAT1), Niemann-Pick type C1 (NPC1), and proprotein convertase subtilisin/kexin type 9 (PCSK9).” | 0.98 | hgnc_dict_v1 |
| gene | PCSK9 | “Targeting of PCSK9 in the Management of Alzheimer's Disease: Expanding the New Potential Key Player.” | 0.98 | hgnc_dict_v1 |
| gene | PCSK9 | “We also identified several rare, intermediate, and most common gene variants in cholesterol associated genes LDLR, LDLRAD2, LDLRAD3, APOA2, APOA3, APOA4, APOA5, and PCSK9.” | 0.98 | hgnc_dict_v1 |
| gene | PCSK9 | “The proband responded remarkably to ezetimibe monotherapy, while his children required combination therapy with high-intensity rosuvastatin and PCSK9 inhibitor Evolocumab for LDL-C reduction.” | 0.98 | hgnc_dict_v1 |
| gene | PCSK9 | “The review further evaluates novel therapeutic approaches, ranging from established lipid-lowering agents (e.g., statins, PCSK9 inhibitors, inclisiran, and bempedoic acid) to anti-inflammatory strategies (e.g., IL-1β and IL-6 inhibitors) and potential STING-targeted interventions.” | 0.98 | hgnc_dict_v1 |
| gene | PCSK9 | “Proteomic markers like proprotein convertase subtilisin/kexin type 9 (PCSK9) and retinol binding protein 4 (RBP4) are being evaluated for cardiovascular risk stratification independent of body mass index (BMI).” | 0.98 | hgnc_dict_v1 |
| gene | PCSK9 | “Identification of genetic risk variants in PCSK9 gene and its association with myocardial infarction in Pakistani Pashtun population.” | 0.98 | hgnc_dict_v1 |
| gene | PCSK9 | “Structural dynamics of PCSK9 loss-of-function variants: implications for LDL cholesterol regulation and cardiovascular risk.” | 0.98 | hgnc_dict_v1 |
| gene | PCSK9 | “Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) inhibitors (alirocumab, evolocumab) and inclisiran offer greater low-density lipoprotein cholesterol (LDL-C) reduction and improved outcomes beyond statins and ezetimibe, but high costs raise affordability concerns in low- and middle-income countries.” | 0.98 | hgnc_dict_v1 |
| gene | PCSK9 | “Molecular docking studies assessed charantin's binding interactions with key lipid-regulating proteins (HMGCR, PCSK9, LDLR, PPAR-α, PI3K).” | 0.98 | hgnc_dict_v1 |
| gene | PCSK9 | “Medical and Financial Consequences of Using PCSK9 Inhibitors for Managing Hypercholesterolemia in Saudi Arabia: A Historical Cohort Study.” | 0.98 | hgnc_dict_v1 |
| gene | PCSK9 | “Studies have revealed the relationship between polymorphisms in genes such as proprotein convertase subtilisin/kexin type 9 (PCSK9), cholesteryl ester transfer protein (CETP), and cyclin-dependent kinase inhibitor 2B antisense RNA 1 (CDKN2B-AS1), which are involved in lipid metabolism, inflammation, and endothelial function.” | 0.98 | hgnc_dict_v1 |
| gene | PCSK9 | “These findings underscore the need for structured follow-up, treatment intensification, and broader use of advanced therapies such as proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors to close the real-world treatment gap.” | 0.98 | hgnc_dict_v1 |
| gene | PCSK9 | “Evolocumab ameliorates myocardial fibrosis and improves metabolic syndrome-induced cardiac dysfunction in rats via inhibiting PCSK9/NLRP3 inflammasome and Caspase-1 / IL-1β pathways.” | 0.98 | hgnc_dict_v1 |
| gene | PCSK9 | “Inclisiran, a small interfering RNA (siRNA) therapy, lowers low density lipoproteins cholesterol (LDL-C) by targeting proprotein convertase subtilisin/kexin type 9 (PCSK9).” | 0.98 | hgnc_dict_v1 |
| gene | PCSK9 | “METHODS: This study included RCTs assessing the effect of PCSK9 inhibitors on cardiovascular events.” | 0.98 | hgnc_dict_v1 |
| gene | PCSK9 | “This includes the HMG-CoA reductase, PPARα/γ, PCSK9, Cyp7a1, and ATP-citrate lyase.” | 0.98 | hgnc_dict_v1 |
| gene | PCSK9 | “Advanced biomolecular spectroscopic profiling of cardiovascular disease macromolecular markers: SIL-6, IL-9, LpA, ApoB, PCSK9 and NT-ProBNP for rapid in-situ detection and monitoring.” | 0.98 | hgnc_dict_v1 |
| gene | PCSK9 | “The Effect of PCSK9 Inhibitors on LDL-C Target Achievement in Patients with Homozygous Familial Hypercholesterolemia: A Retrospective Cohort Analysis.” | 0.98 | hgnc_dict_v1 |
| gene | PCSK9 | “Alirocumab boosts antioxidant status and halts inflammation in rat model of sepsis-induced nephrotoxicity via modulation of Nrf2/HO-1, PCSK9/HMGB1/NF-ᴋB/NLRP3 and Fractalkine/CX3CR1 hubs.” | 0.98 | hgnc_dict_v1 |
| gene | PCSK9 | “The biochemical findings were supported by in silico data showing the affinity of ARB to bind LDL-R PCSK9 binding domain, HMGCR, FAS, and E-NTPDase.” | 0.98 | hgnc_dict_v1 |
| gene | PCSK9 | “Potential use of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibition and prevention method in viral infection.” | 0.98 | hgnc_dict_v1 |
| gene | PCSK9 | “Correction to: The Effect of PCSK9 Inhibitors on LDL-C Target Achievement in Patients with Homozygous Familial Hypercholesterolemia: A Retrospective Cohort Analysis.” | 0.98 | hgnc_dict_v1 |
| gene | PCSK9 | “PCSK9 Inhibitors: Focus on Evolocumab and Its Impact on Atherosclerosis Progression.” | 0.98 | hgnc_dict_v1 |
| gene | PCSK9 | “Retraction Note: Potential use of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibition and prevention method in viral infection.” | 0.98 | hgnc_dict_v1 |
| gene | PCSK9 | “Most patients were on ezetimibe (92%), high-dose statins ( 84%) and PCSK9 inhibitors (32%).” | 0.98 | hgnc_dict_v1 |
| gene | PCSK9 | “Protein structural insights into a rare PCSK9 gain-of-function variant (R496W) causing familial hypercholesterolemia in a Saudi family: whole exome sequencing and computational analysis.” | 0.98 | hgnc_dict_v1 |
| gene | PCSK9 | “Alternatives to statins are PCSK9 inhibitors which are administered subcutaneously every two or four weeks.” | 0.98 | hgnc_dict_v1 |
| gene | PCSK9 | “The development of atherosclerosis risk scores specific for heterozygous FH and the use of subclinical coronary atherosclerosis imaging help with identifying higher-risk individuals who may benefit from further cholesterol lowering with PCSK9 inhibitors.” | 0.98 | hgnc_dict_v1 |
| gene | PCSK9 | “PCSK9 pathway-noncoding RNAs crosstalk: Emerging opportunities for novel therapeutic approaches in inflammatory atherosclerosis.” | 0.98 | hgnc_dict_v1 |
| gene | PCSK9 | “The hepatic mRNA levels of cholesterol metabolism genes (APOB, PCSK9, HMGCR, LDLR, and CYP7A1) in the HCD group also tended toward increased cholesterol production and reduced cholesterol clearance.” | 0.98 | hgnc_dict_v1 |
| gene | PCSK9 | “PCSK9 inhibitors and ezetimibe for the reduction of cardiovascular events: a clinical practice guideline with risk-stratified recommendations.” | 0.98 | hgnc_dict_v1 |
| gene | PCSK9 | “Acaudina molpadioides mediates lipid uptake by suppressing PCSK9 transcription and increasing LDL receptor in human liver cells.” | 0.98 | hgnc_dict_v1 |
| gene | PCSK9 | “Differential associations of statin treatment and polymorphism in genes coding for HMGCR and PCSK9 to risk for insomnia.” | 0.98 | hgnc_dict_v1 |
| gene | PCSK9 | “From 2013 to 2018, consumption of low-density lipoprotein lowering therapies increased (statins 3.99%; ezetimibe 4.01%; proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors 104.47%).” | 0.98 | hgnc_dict_v1 |
| gene | PCSK9 | “Impact of PCSK9, WDR12, CDKN2A, and CXCL12 Polymorphisms in Jordanian Cardiovascular Patients on Warfarin Responsiveness and Sensitivity.” | 0.98 | hgnc_dict_v1 |
| gene | PCSK9 | “Reference single nucleotide polymorphisms (SNPs) of these variants are rs5174, rs11591147, rs2259816, rs111245230, rs3782886 and rs2259820, referring to genes LRP8, PCSK9, HNF1A, SVEP1, BRAP and HNF1A, respectively.” | 0.98 | hgnc_dict_v1 |
| gene | PCSK9 | “In 2017, PCSK9 inhibitors accounted for $317.3 million and $14.2 million in Medicare and Medicaid expenditures, respectively.” | 0.98 | hgnc_dict_v1 |
| gene | PCSK9 | “PURPOSE: This post-hoc analysis examined whether age modified the efficacy and safety of alirocumab, a PCSK9 inhibitor, in patients with heterozygous familial hypercholesterolemia (HeFH), using pooled data from four 78-week placebo-controlled phase 3 trials (ODYSSEY FH I, FH II, LONG TERM, and HIGH FH).” | 0.98 | hgnc_dict_v1 |
| gene | PCSK9 | “Familial hypercholesterolemia (FH) is a monogenic dominant inherited disorder of lipid metabolism characterized by elevated low-density lipoprotein levels, and is mainly attributable to mutations in low-density lipoprotein receptor (LDLR), apolipoprotein B (APOB), and proportein convertase subtilisin/kexin type 9 (PCSK9) genes.” | 0.98 | hgnc_dict_v1 |
| gene | PCSK9 | “PCSK9 and inflammation: a review of experimental and clinical evidence.” | 0.98 | hgnc_dict_v1 |
| gene | PCSK9 | “Genotyping and Frequency of PCSK9 Variations Among Hypercholesterolemic and Diabetic Subjects.” | 0.98 | hgnc_dict_v1 |
| gene | PCSK9 | “Definite FH includes: (1) elevated LDL-C (≥ 8.50 mmol/L); or (2) LDL-C ≥ 5.0 mmol/L (for age 40 years or older; ≥ 4.0 mmol/L if age younger than 18 years; and ≥ 4.5 mmol/L if age is between 18 and 39 years) when associated with at least 1 of: (1) tendon xanthomas; or (2) causal DNA mutation in the LDLR, APOB, or PCSK9 genes in the proband or first-degree relative.” | 0.98 | hgnc_dict_v1 |
| gene | PCSK9 | “Thus, we applied Mendelian randomization to assess any potential neuropsychiatric adverse effects of conventional lipid-lowering drugs such as statins, proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors, and ezetimibe.” | 0.98 | hgnc_dict_v1 |
| gene | PCSK9 | “BACKGROUND: The proprotein convertase subtilisin/kexin type 9 (PCSK9) is a secreted protein that interacts with the low-density lipoprotein (LDL) receptor at the surface of hepatocytes to regulate circulating LDL cholesterol levels.” | 0.98 | hgnc_dict_v1 |
| gene | PCSK9 | “BACKGROUND: Evolocumab, a proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitor, has been shown to reduce low-density lipoprotein levels by up to 60%.” | 0.98 | hgnc_dict_v1 |
| gene | PCSK9 | “Mutations in the LDLR, APOB, and PCSK9 genes are known to cause FH.” | 0.98 | hgnc_dict_v1 |
| gene | PCSK9 | “Moreover, a substantial deficit was identified in the awareness of various clinical algorithms to diagnose patients with FH, cascade screening, specialist lipid services, and the existence of statin alternatives, such as proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors.” | 0.98 | hgnc_dict_v1 |
| gene | PCSK9 | “In order to find the causative genetic variant in this family, direct exon sequencing of the LDLR, APOB and PCSK9 genes was performed.” | 0.98 | hgnc_dict_v1 |
| gene | PCSK9 | “The underlying molecular basis of FH is the presence of mutations in one or more genes in the low-density lipoprotein receptor (LDLR), apolipoprotein B (APOB) or proprotein convertase subtilisin/kexin 9 (PCSK9).” | 0.98 | hgnc_dict_v1 |
| gene | PCSK9 | “Albeit the diagnosis of some medical Familial Hypercholesterolemia (FH) cases are due to mutations in PCSK9, APOB, or LDLR, detection of mutation rate and profiles relies heavily on different gene pools and ethnicity.” | 0.98 | hgnc_dict_v1 |
| gene | PCSK9 | “Abbreviations used: HC: Hypercholesterolemia, WHO: World Health Organization, BAS: Bile acid sequestrant, PCSK9: Proprotein convertase subtilisin kexin type 9, ALE: Artichoke leaf extract, CCL: Cynara cardunculus leaf extract, CCP: Cynara cardunculus pulp extract, BWG%: Body weight gain%, FER: Food-efficiency ratio.” | 0.98 | hgnc_dict_v1 |
| gene | PCSK9 | “Expressions of proprotein convertase subtilisin/kexin type 9 (PCSK9), serum amyloid A1, and cytokine were measured by enzyme-linked immunosorbent assay.” | 0.98 | hgnc_dict_v1 |
| gene | PCSK9 | “The treatment of hypercholesterolemia entered in a new phase of development with the introduction of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors in the market.” | 0.98 | hgnc_dict_v1 |
| gene | PCSK9 | “Decreased PCSK9 expression in human hepatocellular carcinoma.” | 0.98 | hgnc_dict_v1 |
| gene | PCSK9 | “A semi-automated mass spectrometric immunoassay coupled to selected reaction monitoring (MSIA-SRM) reveals novel relationships between circulating PCSK9 and metabolic phenotypes in patient cohorts.” | 0.98 | hgnc_dict_v1 |
| gene | PCSK9 | “Proprotein convertase subtilisin/kexin type 9 (PCSK9): lessons learned from patients with hypercholesterolemia.” | 0.98 | hgnc_dict_v1 |
| gene | PCSK9 | “Plasma PCSK9 levels are elevated with acute myocardial infarction in two independent retrospective angiographic studies.” | 0.98 | hgnc_dict_v1 |
| gene | PCSK9 | “BACKGROUND: Although statin therapy is known to increase concentrations of PCSK9, whether this effect is related to the magnitude of LDL reduction is uncertain.” | 0.98 | hgnc_dict_v1 |